A Phase I/IB Study fo AZD2171 and Temsirolimus in Patients With Advanced Gynecological Malignancies.

Trial Profile

A Phase I/IB Study fo AZD2171 and Temsirolimus in Patients With Advanced Gynecological Malignancies.

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 09 May 2017

At a glance

  • Drugs Cediranib (Primary) ; Temsirolimus (Primary)
  • Indications Cervical cancer; Endometrial cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 04 May 2017 Planned End Date changed from 1 Sep 2013 to 1 Apr 2018.
    • 26 Aug 2013 Planned End Date changed from 1 Feb 2012 to 1 Sep 2013 as reported by ClinicalTrials.gov.
    • 08 Sep 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top